AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PRGO · NYSE · Drug Manufacturers - Specialty & Generic

Perrigo (PRGO)

Makes consumer self-care products through Americas and international operating segments.

$14.08

vs last close−0.23 (−1.61%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	1,124	1,157	1,082	1,066	1,088	1,138	1,044	1,056	1,043	1,110	969	1,023
Cost of revenue	713	730	724	671	683	752	652	693	666	747	644	709
Gross profit	411	427	358	395	404	386	392	363	377	362	326	314
	349	443	413	421	324	272	345	318	305	278	292	291
Research & development	30	30	29	29	26	28	27	22	25	22	25	24
	304	307	306	301	272	235	281	273	222	−249	130	230
Selling & marketing	178	178	175	175	155	140	169	160	127	70	130	130
General & administrative	126	129	130	126	117	95	112	113	94	−319	0	100
Other expenses	16	107	78	91	27	9	38	22	58	505	138	37
Operating income	62	−16	−55	−27	80	114	47	45	73	85	34	24
	−43	−39	−43	−48	−59	−44	−39	−42	−50	−1,416	−443	82
Interest expense	44	43	43	44	58	43	39	40	54	30	41	38
Other non-operating income	−1	−4	0	3	1	1	0	3	−4	1,387	402	−120
Income before tax	19	−54	−99	−74	22	70	8	3	22	−1,332	−409	105
Income tax expense	4	−27	−103	32	39	112	8	4	10	83	−19	17
Net income from continuing operations	15	−28	4	−106	−18	−42	0	−1	13	−1,415	−390	89
Discontinued operations	−1	−5	−2	−3	−3	−3	−7	−8	−5	−4	−9	−14
Other adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Net income	14	−32	2	−108	−21	−45	−6	−8	8	−1,418	−399	75
EPS, basic	$0.11	−$0.24	$0.01	−$0.77	−$0.15	−$0.32	−$0.05	−$0.06	$0.05	−$10.23	−$2.87	$0.54
EPS, diluted	$0.11	−$0.24	$0.01	−$0.77	−$0.15	−$0.32	−$0.05	−$0.06	$0.05	−$10.23	−$2.87	$0.53
Weighted average shares, basic	136	136	137	137	138	138	138	138	139	139	139	139
Weighted average shares, diluted	137	136	138	137	138	138	138	138	139	139	139	140
EBITDA	154	74	26	52	162	193	127	129	162	−1,246	−284	144
Depreciation & amortization	91	86	81	82	82	80	80	86	85	56	83	0
EBIT	63	−12	−56	−30	79	113	47	43	76	−1,302	−368	144